RIPK2 inhibits the proliferation and apoptosis of glioma cells by activating the NF-κB pathway and the mitogen-activated protein kinase (P38) pathway, and it inhibits tumour growth by regulating TRAF3 expression instead of the NF-κB pathway [22]. This evidence concerns the gene NFKB1 and central nervous system cancer.